$33.4 Billion Today, $328 Billion by 2033: Inside the Edge Computing Market's Great Sprint

Enterprises are moving compute closer to where data is created. Factories, hospitals, retail stores, telecom towers, and vehicles all produce data that can't always wait for a round trip to a distant cloud region. Edge computing handles that processing locally. According to Grand View Research, it is quickly becoming a foundational layer of digital infrastructure.

Market Overview & Growth Projections

The global edge computing market was valued at USD 33.4 billion in 2025. It is estimated at USD 46.7 billion in 2026 and is projected to reach USD 328.0 billion by 2033, a CAGR of 32.1% from 2026 to 2033.

A few segment-level numbers show where the money sits today:

• Component: Hardware led in 2025 with a 41.8% revenue share, as growing volumes of IoT and IIoT data push enterprises to deploy edge gear that offloads cloud and data centers. Software is the fastest-growing component, with a projected CAGR above 37% through 2033.
• Organization size: Large enterprises held 67.5% of the market in 2025. Small and medium enterprises are expected to grow fastest as edge solutions become more affordable and scalable.
• Region: North America led with a 36.7% revenue share in 2025, supported by connected-factory adoption in the U.S. and a strong startup ecosystem. Asia Pacific is the fastest-growing region, at a CAGR of around 39%, driven by 5G rollout, Industry 4.0, and a fast-expanding connected-device base.

The market is moderately fragmented. Cloud giants, telcos, hardware makers, software vendors, and specialist startups all compete, with medium-to-high M&A activity as players build out their edge portfolios.

Want to see the full forecast, segment data, and country-level breakdowns? Download Free Sample Report

Core Drivers of the Edge Shift

1. Demand for low-latency, real-time processing. Autonomous vehicles, industrial automation, remote monitoring, video analytics, and AR all need near-instant responses. Processing data near its source cuts latency and bandwidth use while speeding up decisions.
2. IoT proliferation. Billions of connected sensors and devices generate more data than is practical, or efficient, to send to a central cloud. Local processing keeps operations reliable and manageable.
3. 5G rollout. Ultra-low latency and high throughput make 5G a natural partner for the edge. Telecom providers are integrating Multi-Access Edge Computing (MEC) into their networks to deliver more responsive services for use cases like smart cities and remote surgery.
4. AI and ML at the edge. Running inference locally gives businesses immediate insights without depending entirely on centralized cloud systems. That matters most in defense, retail, and energy, and it also improves privacy and reduces connectivity dependence.
5. Data sovereignty and regulation. Rules on data privacy and cross-border data flows are pushing organizations toward localized infrastructure. Germany's emphasis on GDPR compliance is one example.

A reality check: The report also flags restraints. High deployment costs, the complexity of managing and securing geographically dispersed edge nodes, integration with existing cloud and on-prem systems, and a shortage of skilled talent can all slow adoption, especially for smaller organizations.

Core Applications Across Key Verticals

Industrial IoT (IIoT) was the largest application segment in 2025, with a 22.7% share. Edge computing supports predictive maintenance and efficiency gains by processing sensor and machine data locally. It also gives manufacturers and logistics operators a scalable path to modernize legacy systems.

Manufacturing was the leading industry vertical, with a 20.1% share. On the factory floor, edge enables real-time quality control, machine automation, edge-powered robotics, and AI-driven inspection, all of which reduce downtime.

Healthcare is projected to be the fastest-growing vertical through 2033. Hospitals and clinics are adopting edge for patient record management, continuous patient monitoring, and remote patient care.

AR/VR is the fastest-growing application. Immersive experiences demand rapid computational response, and placing infrastructure close to users cuts latency and bandwidth consumption. 5G and growing investment in metaverse and industrial AR platforms add momentum.

Other applications the report tracks include video analytics, connected cars, smart grids, traffic management, asset tracking, security and surveillance, and smart cities. The energy and utilities, retail, transportation and logistics, and telecom and IT verticals are all adopting edge as well.

Leading Competitors and Ecosystem Players

The competitive landscape spans hyperscalers, networking and hardware vendors, semiconductor leaders, and industrial automation specialists. The report names these key companies:

• Amazon Web Services
• Microsoft Corporation
• Google LLC
• Cisco Systems
• Hewlett Packard Enterprise
• Intel Corporation
• Huawei Technologies
• Schneider Electric
• Siemens
• General Electric Company

How the major players are positioning themselves:

• AWS extends its infrastructure to telecom networks and local environments through AWS Wavelength, AWS Outposts, and AWS Greengrass.
• Microsoft offers Azure Stack Edge and Azure IoT for real-time decisions and AI/ML inference at the edge, with a focus on manufacturing, healthcare, and logistics.
• Schneider Electric pairs power, cooling, and IT in compact micro data centers through EcoStruxure, with a sustainability angle.
• Siemens leverages its automation heritage with the Industrial Edge platform for predictive maintenance and quality assurance on the factory floor.

Recent moves show where the ecosystem is heading:

• Google upgraded its Distributed Cloud Edge platform with AI models and Anthos features, targeting telecom providers (April 2025).
• Intel unveiled Meteor Lake processors built for edge inference and real-time analytics in industrial settings (March 2025).
• Microsoft expanded its edge strategy for utilities navigating grid modernization and distributed energy integration (February 2025).

Semiconductor leaders such as NVIDIA, Intel, and AMD are also shipping processors optimized for edge workloads. The report expects this to unlock further long-term opportunities.

The Bottom Line

With a 32.1% CAGR, a rapidly maturing ecosystem, and demand spanning manufacturing floors to operating rooms, edge computing is moving from experiment to infrastructure. The key questions now are which segments, regions, and partners will capture the most value.

Have specific questions about the edge computing market? Get answers directly from the report's research team. Speak to Analyst

From USD 851B to USD 2.79T: Inside the Healthcare IT Market's Great Digital Sprint

Healthcare is going digital faster than almost any other industry. Grand View Research values the global healthcare IT market at USD 851.4 billion in 2025, and the pace of growth is striking. This post covers the market's core metrics, the forces behind its growth, the risks to plan for, and the technologies leading the shift.

1. Core Market Specifications & Metrics

The global healthcare IT market was valued at USD 851.4 billion in 2025 and is estimated at USD 981.1 billion in 2026. It is projected to reach USD 2,790.1 billion by 2033, growing at a CAGR of 23.2% from 2026 to 2033.

Regional picture: North America led in 2025 with a 51.4% revenue share, driven largely by the U.S. The Middle East & Africa is the fastest-growing region, with a 31.4% CAGR. Latin America is also growing quickly at 24.3%.

Segment leaders:

• Application: Revenue cycle management holds the largest share at 45.2%, driven by demand for workflow optimization and synchronized management software. E-prescribing is expected to be among the fastest growers, with a projected 37.0% CAGR.
• Delivery mode: Solutions, including EHRs, analytics platforms, RCM systems, telehealth and hospital information systems, hold the largest share and are also expected to grow fastest.
• End use: Healthcare providers lead today. The life sciences segment is forecast to grow fastest, thanks to clinical trial management, real-world evidence and regulatory data management needs.

2. Key Macro Trends & Growth Drivers

Smartphones and connectivity are the foundation. About 78% of the world's population used smartphones as of 2023 (ITU), and roughly 71% had internet access in 2024 (World Bank). That reach underpins mHealth apps, remote monitoring, medication adherence tools and cloud-based telehealth.

Out-of-hospital care is growing. Demand for remote patient monitoring, an aging population and rising chronic disease burden are pushing care into homes and outpatient settings. Japan is a good example: Sompo partnered with TytoCare to deploy AI-powered remote examination devices across 301 nursing homes and elder care centers.

Value-based care needs centralized data. Particularly in the U.S., the shift toward value-based models is driving demand for unified records and EHR-based management. Nearly 9 in 10 U.S. physicians had adopted EHRs by 2021, and that base is now fueling demand for interoperability, analytics and population health tools.

Government support is accelerating adoption. Examples include:

• United States: the HITECH Act and Meaningful Use programs
• Germany: the Digital Act (DigiG) and DiGA reimbursement pathway for approved digital health apps
• United Kingdom: NHS-led digital transformation
• Australia: HealthSmart and HealthConnect
• Middle East: large national digital health initiatives

Investment and M&A are active. Vendors are expanding capabilities and geographic reach through acquisitions, partnerships and new offices. Clario's acquisition of WCG's eCOA business is one example from 2025.

Want to see the data first? Get market estimates, trend analyses and forecasts in a free sample. Download Free Sample

3. Restraints & Risk Mitigation

The source report focuses mainly on growth drivers rather than listing restraints. The risks below combine evidence from the report with common industry challenges, so treat them as a practical framework rather than the report's own findings.

Regulatory and privacy complexity. Vendors must navigate HIPAA, the FTC's Health Breach Notification Rule, FDA oversight of digital health and varying regional rules. Mitigation: build compliance into product design, and track regional frameworks such as DiGA early.

Fragmented systems and interoperability gaps. The report's senior care case study shows how disparate systems and manual workflows hinder compliance and data visibility. Mitigation: standardize on a unified platform such as EHR plus eMAR, invest in data integration, and pair rollouts with hands-on training.

Uneven digital adoption. Adoption differs across providers, as the report notes for Oregon's EHR use. Mitigation: use phased deployments, train-the-trainer programs and vendor support tailored to smaller or less digitized providers.

AI trust, safety and data quality. AI is spreading into documentation, coding and clinical support, which raises the stakes for accuracy and privacy. Mitigation: use clinically grounded models, keep humans in the loop for key decisions, and apply strong privacy and security standards.

Intense vendor competition. Many vendors compete in EHR and e-prescribing. Mitigation: differentiate through specialization, partnerships and AI-native features.

4. Dominant Technology Trends

AI across the care and revenue lifecycle. AI adoption is accelerating in five core areas:

• Revenue cycle management: In July 2025, Omega Healthcare expanded its Microsoft collaboration to launch 20+ generative and agentic AI solutions covering coding, denial management and appeals. In October 2025, athenahealth launched AI-native enhancements aimed at cutting practice administrative workload by over 50%.
• EHRs: Athenahealth added GenAI-based document labeling, clinical summaries and a patient-history assistant to athenaOne. Core Solutions launched Cx360 Intelligence for behavioral health, with real-time AI summaries and ambient documentation in 17 languages.
• Tele-healthcare: AI-driven triage, chatbots and remote diagnostics are extending access. VSee Health's Project MAMA in the rural Philippines pairs local-language chatbots with portable ultrasound and remote OB-GYN consults.
• Population health: Percipio Health raised USD 20 million to build AI-powered monitoring using smartphone-based vision and vocal biomarkers.
• Healthcare analytics: Oracle Health, Cleveland Clinic and G42 are partnering on an AI-powered global healthcare platform built on Oracle Cloud.

Cloud-native platforms. Cloud-based delivery is becoming standard for imaging, EHR and analytics. DeepHealth's cloud-native PACS and AI mammography tools, launched at ECR 2025, are one example.

Natural-language data access. Tools like Suvoda's Sofia AI assistant let users query, analyze and visualize data conversationally, making analytics usable beyond data teams.

Integrated "super apps" and patient engagement. Platforms such as TruDoc's Super Health App combine facial-scan vitals, wearable sync, multilingual AI chat and lab report summaries in one experience.

Data infrastructure for analytics. Partnerships like Kythera Labs' with Preverity and GAM show growing focus on integration, de-identification and data mastering as the backbone of compliant analytics.

The Bottom Line

With a projected 23.2% CAGR, healthcare IT is a major transformation story for providers, payers, life sciences companies and technology vendors alike. Success will depend on pairing AI and cloud innovation with strong interoperability, compliance and change management.

Want this analysis tailored to your needs? Add regions, segments or data points to match your strategy, with free customization included. Customize This Report

Sugarcane's 38.6% Grip on the Lactic Acid Market: Is Anyone Close?

The global lactic acid market was valued at USD 2.8 billion in 2025. Grand View Research projects it will reach USD 3.0 billion in 2026 and USD 5.0 billion by 2033, a CAGR of 7.3%. Lactic acid is a fermentation-derived building block used in food preservation, drug formulation, skincare, and biodegradable plastics. As industries move away from petroleum-based inputs, it is becoming central to the bio-based economy.

Key Market Segmentation

The market is segmented by raw material, application, and region.

By raw material

The report covers corn, sugarcane, cassava, yeast extract, and other crops.

• Sugarcane leads. It held a 38.6% revenue share in 2025. Low cost, high sugar yield, and efficient fermentation make it the preferred feedstock for large-scale producers.
• Yeast extract grows fastest. It is forecast to expand at a 9.6% CAGR from 2026 to 2033. Producers value it for improving fermentation efficiency, yield, and process consistency.

By application

The report covers industrial, food & beverages, pharmaceuticals, personal care, polylactic acid (PLA), and other applications.

• Food & beverages is the largest. It accounted for a 28.1% revenue share in 2025. Lactic acid works as an acidulant, preservative, pH regulator, and flavor enhancer.
• Pharmaceuticals grows fastest. It is expected to grow at an 8.4% CAGR through 2033. Demand comes from drug formulation, controlled-release systems, and medical-grade polymers, where high purity and biocompatibility matter.

By region

• North America led in 2025 with a 39.6% revenue share. The U.S. was the largest national market, supported by strong R&D activity and fast commercialization of bio-based polymers.
• Asia Pacific held a 26.1% share and is the fastest-growing region. Abundant feedstock, expanding manufacturing, and government incentives for bioplastics support its growth. China stands out for its PLA capacity expansion.
• Europe is driven by strict environmental policy and circular bioeconomy investment, with Germany a key hub.
• Latin America benefits from cost-effective agricultural feedstock.
• Middle East & Africa is growing as food processing and healthcare modernize.

Want the Full Picture? Download Free Sample: preview the report's data points, trend analysis, and forecasts.

Primary Demand Drivers

1. The shift to bio-based and sustainable products. Companies and regulators want to reduce reliance on petroleum-based chemicals. Lactic acid comes from renewable feedstocks such as corn and sugarcane, so it fits that goal across many industries. Government support for the bioeconomy and sustainable manufacturing adds momentum.
2. PLA and biodegradable plastics. Lactic acid is the core feedstock for PLA, which is gaining ground in packaging, consumer goods, food service, textiles, agriculture, and 3D printing. Growing PLA production capacity creates steady demand for polymer-grade lactic acid.
3. Clean-label food and beverage formulation. Consumers increasingly prefer natural, recognizable ingredients. Lactic acid's safety profile and multiple functions make it a go-to choice for premium food and beverage brands.
4. Pharmaceutical and personal care growth. Healthcare applications need high-purity, biocompatible ingredients, and personal care brands are reformulating around natural actives. Both are pushing demand toward specialty grades.
5. Fermentation technology improvements. Better yields, feedstock utilization, and purification lower costs and improve product quality, which supports adoption in price-sensitive markets.

The main restraint is feedstock price volatility. Crop yields, weather, and agricultural policy can all move input costs. High-purity production also requires advanced and costly processing, and petrochemical alternatives remain competitive where price matters most.

Competitive Landscape

The market is concentrated. A few established players hold an edge through advanced fermentation technology, global distribution, and economies of scale, which limits easy entry for smaller manufacturers.

Key companies profiled: Futerro, BASF SE, Galactic, Henan Jindan Lactic Acid Technology Co. Ltd., Corbion, thyssenkrupp AG, Dow, Cellulac, Jungbunzlauer Suisse AG, and TEIJIN LIMITED.

Established players (BASF SE, Corbion, Jungbunzlauer, Dow, TEIJIN, thyssenkrupp)

• Strategy: expand capacity, invest in fermentation and process optimization, and secure long-term supply agreements and partnerships.
• Strengths: global manufacturing footprint, deep R&D resources, and established relationships with food, pharma, industrial, and PLA customers.
• Challenges: high capital requirements, exposure to feedstock and energy costs, and regulatory compliance burdens.

Emerging and specialized players (Futerro, Galactic, Henan Jindan, Cellulac)

• Strategy: focus on specialty grades, bioplastics, and application-specific products, often through technology licensing and regional partnerships.
• Strengths: flexibility, strong sustainability positioning, and faster commercialization of new products.
• Challenges: smaller capacity and reach, tighter financial resources, and pricing pressure from larger integrated producers.

Recent developments

• March 2025: Futerro began the engineering and FEED phase for a European biorefinery in France. The site is designed to integrate lactic acid production, PLA manufacturing, and recycling.
• May 2025: Galactic expanded its fermentation-based ingredient portfolio with Galimax Flavor O-50, a natural oregano-derived flavor solution that also helps maintain product freshness.

What This Means for Industry Stakeholders

Growth will be shaped by who can combine cost-efficient feedstock sourcing, high-purity production, and integration into PLA and specialty applications. Producers that scale responsibly and tailor grades to food, pharma, and polymer customers are best placed to capture the next phase of demand.

Speak to Analyst: get your questions answered directly by the report's research team.

Why the Immunoassay Market Is Quietly Powering Precision Medicine

Immunoassays are at the center of modern diagnostics. They detect the antibodies, hormones, proteins, and pathogens that drive decisions in oncology, cardiology, infectious disease, and neurology. Grand View Research values the global immunoassay market at about USD 28.1 billion in 2025. It expects USD 29.3 billion in 2026 and USD 40.3 billion by 2033, a CAGR of 4.6% from 2026 to 2033.

Below is where the market stands today, who is competing for share, and what is likely to shape the next few years.

Market Breakdown & Segmentation

The market is segmented by product, technology, application, specimen, end-use, and region. Here is the 2025 picture:

• Product: Reagents and kits lead with a 66.2% share. Software and services is the fastest-growing segment.
• Technology: Enzyme immunoassays (EIA) hold a 64.1% share. Rapid tests are expected to grow fastest.
• Application: Infectious disease leads with a 30.1% share and a projected 5.5% CAGR.
• Specimen: Blood leads with a 41.4% share. Urine is the fastest-growing specimen type.
• End-use: Hospitals lead with a 32.4% share. Clinical laboratories are poised for robust growth.
• Region: North America leads with a 47.3% share. Asia Pacific is the fastest-growing region.

Product. Reagents and kits dominate because every test run consumes them. Demand is steady across ELISA, chemiluminescence (CLIA), lateral flow, and rapid antigen formats. Software and services is smaller but growing fastest, as labs adopt automation, AI-enabled analytics, cloud data management, and outsourced testing support.

Technology. EIA's lead reflects its sensitivity, specificity, and compatibility with automated lab systems. Rapid tests are the challenger, helped by microfluidics, nanotechnology, and biosensor advances that make portable testing more accurate.

Application. Infectious disease testing leads, supported by persistent burdens such as tuberculosis (about 1.23 million deaths globally in 2024, per WHO). Oncology and autoimmune testing are also set to grow significantly as biomarker-driven care and companion diagnostics expand.

Specimen and end-use. Blood remains the workhorse sample type. Hospitals lead end-use because of their high testing volumes and investment in automated platforms. Urine-based testing is gaining ground in point-of-care and home settings because collection is non-invasive.

Region. North America's lead rests on advanced healthcare infrastructure, favorable reimbursement, and the presence of major manufacturers. Asia Pacific is expected to grow fastest as healthcare infrastructure improves, chronic disease burdens rise, and large patient populations gain access to diagnostics. China, Japan, and India are the key markets.

Major Competitors

The report profiles these major players:

• Abbott
• Siemens Healthineers
• Danaher Corporation (Beckman Coulter)
• bioMérieux
• QuidelOrtho (Quidel and Ortho Clinical Diagnostics)
• Sysmex Corporation
• Bio-Rad Laboratories
• F. Hoffmann-La Roche
• Becton, Dickinson and Company
• Thermo Fisher Scientific

Established players like Abbott compete on scale: automated high-throughput platforms, global distribution, deep R&D, and regulatory expertise. Their trade-offs are high compliance and manufacturing costs, long approval timelines, and platforms that can be hard to adopt in resource-limited settings.

Emerging players like QuidelOrtho focus on rapid, point-of-care, and cost-effective testing. They tend to move faster and adapt to regional needs, though they face smaller distribution networks and tighter resources for large-scale R&D.

Recent moves show where competition is heading:

• Roche completed its acquisition of LumiraDx's point-of-care technology in July 2024, broadening its decentralized testing platform.
• QuidelOrtho signed a supply agreement with Lifotronic in February 2026, adding analyzer platforms and more than 25 additional immunoassays.
• Fujirebio launched its Lumipulse G pTau 217 CSF assay in January 2026, and Roche received CE mark approval for its Elecsys pTau217 blood test in May 2026, both for Alzheimer's biomarker detection.
• Sysmex launched a research-use p-Tau217 assay kit in Europe in April 2026.

Neurodiagnostics, especially blood-based Alzheimer's testing, is becoming a visible battleground.

Want Deeper Insights? Download a Free Sample Report to see the report's structure, market data points, and forecasts.

Core Growth Drivers & Trends

Drivers

1. The rise of chronic and infectious disease. According to WHO figures cited in the report, noncommunicable diseases cause roughly 74% of deaths worldwide. Cardiovascular disease, cancer, diabetes, and autoimmune disorders all require continuous diagnostic monitoring, which keeps immunoassay volumes high in hospitals and labs.
2. Precision medicine. Immunoassays identify biomarkers that predict how patients will respond to specific therapies. Pharmaceutical companies are also building them into drug development pipelines, which supports demand for companion diagnostics.
3. Automation. High-throughput analyzers improve lab efficiency, precision, and turnaround time, and they strengthen the case for centralized laboratory networks.

Trends

• Point-of-care expansion. Lateral flow, microfluidics, and digital immunoassays are moving testing into pharmacies, clinics, and homes. In August 2024, the U.S. FDA authorized the first over-the-counter home immunoassay for syphilis antibodies.
• Multiplexing and AI. Companies are pairing multiplex assays, CLIA, and AI-assisted interpretation to detect several biomarkers at once and improve specificity.
• Consolidation. Mergers, acquisitions, and supply agreements are increasing as companies build out point-of-care and immunochemistry portfolios.
• Regional localization. Partnerships, local manufacturing, and wider distribution networks are central to reaching emerging markets.

The main restraint

Cross-reactivity and false positives remain a challenge, particularly for rapid screening tests during overlapping respiratory outbreaks. Manufacturers are responding with multiplex platforms, CLIA, and AI-based interpretation to improve reliability.

The Bottom Line

The immunoassay market is growing at a steady 4.6% rather than a spectacular pace, but its foundations are strong: aging populations, rising chronic disease, personalized medicine, and a shift toward faster, more decentralized testing. Companies that combine automation, strong biomarker menus, and point-of-care reach will be best placed to capture growth, especially in Asia Pacific.

Customize This Report to add regions, segments, or data points that match your strategy. Grand View Research offers 20% free customization.

From USD 4.7 Billion to 35.8 Billion: The Robotic Process Automation Market's Eight-Year Sprint

Robotic process automation (RPA) started as a way to offload repetitive keystrokes. It is now a core layer of enterprise digital transformation. Here is a look at where the market stands, what is driving it, which sectors lead, and which vendors are shaping the space, based on Grand View Research's latest analysis.

Key Market Dimensions

The global robotic process automation market was valued at USD 4.7 billion in 2025. It is estimated at USD 6.0 billion in 2026 and projected to reach USD 35.8 billion by 2033, a CAGR of 29.0% over 2026-2033.

• By type: Software is the largest segment, with a 70.7% revenue share in 2025. Services (consulting, implementation, training) is the fastest-growing.
• By deployment: Cloud leads, with more than 55% of 2025 revenue, helped by lower infrastructure costs, remote access, and SaaS subscription models. On-premise is still expected to grow at a significant rate, because some organizations want full control over data, access policies, and compliance.
• By operation: Rule-based automation dominates today, but knowledge-based automation, powered by AI, NLP, and machine learning, is the fastest-growing.
• By enterprise size: Large enterprises hold the biggest share. SMEs are growing fastest as vendors close the supply gap with packaged, faster-ROI offerings.
• By region: North America led in 2025 with a 39.0% share. Asia Pacific is the fastest-growing region, with a projected CAGR above 30%, led by China, Japan, and India.

Market Catalysts and Evolving Architecture

Operational scalability. Transaction volumes keep rising while skilled labor stays scarce. RPA lets organizations scale tasks such as data entry, claims processing, order management, and reporting without adding headcount in proportion.

Legacy modernization. Many enterprises run fragmented, ageing systems that are costly to replace. RPA works as a non-intrusive layer on top of existing applications. It bridges old and new systems and speeds up transformation without a full overhaul.

AI convergence. Early RPA handled narrow processes with few decisions and few applications. Embedding machine learning, NLP, and intelligent document processing now lets bots handle unstructured inputs such as emails, documents, and customer queries, and take on judgment-based workflows.

Governance by design. Audit trails, compliance controls, and data-protection frameworks are making automation trustworthy in regulated industries.

Agentic automation. Recent launches show the direction of travel. In November 2025, C3 AI introduced an agentic process automation platform in which autonomous AI agents handle workflows like order-to-cash, procurement, and onboarding, as well as industrial tasks like maintenance and production planning.

In practice, architecture is shifting from standalone task bots toward cloud-native, AI-infused platforms with orchestration, governance, and marketplaces of prebuilt automations. On-premise options remain for control-sensitive workloads.

Want to see the data behind the forecasts? Download Free Sample

Leading Industry Sectors

BFSI is the largest end-use segment. Banks and insurers use RPA for mortgage processing, reconciliation, risk and compliance reporting, cards and payments, and anti-money laundering. Regulatory pressure, security needs, and 24/7 service expectations reinforce adoption.

Pharma and healthcare is the fastest-growing. Vendors now offer healthcare-specific automation for patient data management, billing and claims, scheduling, and regulatory documentation. Growing data volumes, administrative workloads, and compliance demands are pushing demand.

Other sectors covered include retail and consumer goods, IT and telecom, media and education, manufacturing, and logistics, energy, and utilities.

Top Tools and Vendors

The report profiles 15 companies, including:

• UiPath: A major platform vendor. In June 2025 it partnered with HCLTech to scale adoption through joint go-to-market efforts and prebuilt AI agent solutions.
• Automation Anywhere: A cloud-native, web-based platform combining RPA with AI, ML, and analytics, with governance tools and a marketplace of prebuilt automations. It operates in more than 40 countries.
• BlackLine: A cloud platform focused on automating financial close, intercompany accounting, and invoice-to-cash.
• SS&C Blue Prism
• Microsoft
• SAP SE
• Pegasystems
• NICE
• Others profiled: EdgeVerve Systems, FPT Software, NTT Advanced Technology, OnviSource, Tungsten Automation, Uniphore, and WorkFusion.

Services partnerships are also active. In October 2025, Cognizant signed a deal with AP Pension covering BPO, RPA, and administrative process optimization.

The Takeaway

With AI moving RPA from rule-following to reasoning, and with cloud and SME adoption widening the buyer base, the market is on track to grow nearly eightfold between 2025 and 2033. Enterprises that pair automation with strong governance will be best placed to capture the efficiency gains.

Have questions about the numbers or want a tailored view? Speak to Analyst

From USD 79.6 Billion to USD 161.3 Billion: The Customer Relationship Management Market's Seven-Year Sprint

Customer expectations keep rising, and CRM platforms have moved from sales databases to AI-driven engines for personalization, service, and retention. According to Grand View Research, the global customer relationship management market was valued at USD 79.6 billion in 2025. It is projected to reach USD 86.4 billion in 2026 and USD 161.3 billion by 2033, a CAGR of 9.3% from 2026 to 2033.

Core Market Snapshot

• By solution: Customer service led in 2025 with a 22.5% revenue share. Social media monitoring is expected to be the fastest-growing application, at a 17.2% CAGR.
• By deployment: Cloud accounted for 59.4% of revenue in 2025. On-premise remains relevant for organizations with strict data privacy needs.
• By enterprise size: Large enterprises held a 59.2% share, while SMEs are projected to grow fastest, at a 16.2% CAGR.
• By end use: BFSI led with a 22.2% share. IT & telecom is expected to grow at a 16.3% CAGR.

North America led the market with a 40.4% revenue share in 2025, reflecting the concentration of major CRM vendors in the region. These vendors keep investing in AI, automation, analytics, and industry-specific solutions. The U.S. is the largest national market. Asia Pacific is the fastest-growing region, at a projected 16.3% CAGR.

Top Vendors and Market Share

The CRM landscape has two tiers: global platform leaders and agile challengers.

Established players. Grand View Research names Salesforce, Microsoft, SAP, Oracle, and Adobe among the leading vendors, and lists HubSpot with this group in its benchmarking. They compete on:

• Broad portfolios spanning sales, marketing, service, and commerce
• Heavy investment in AI, customer data platforms (CDPs), and analytics
• Large partner ecosystems and global customer bases
• Acquisitions and cloud infrastructure expansion

Their trade-offs are higher implementation and subscription costs, longer onboarding, and integration complexity for smaller organizations.

Emerging players. Zoho, Creatio, Freshworks, SugarCRM, and Insightly target SMEs and the mid-market. They compete on:

• Cloud-native, user-friendly products
• Faster deployment and flexible pricing
• Low-code and no-code customization
• Responsiveness to niche and regional needs

Their limitations are a smaller customer base, lower brand visibility, and tighter R&D budgets than the giants.

The full list of companies profiled in the report also includes ClickUp, Copper CRM, monday.com, Nimble, and Zendesk. The public report summary does not publish vendor-level market share percentages, so the full report is where you will find company share and competitive positioning in detail.

Get a Closer Look at the Data Explore market estimates, trend analyses, and forecasts before you buy. Download Free Sample Report

Emerging Drivers & Trends

1. Generative and agentic AI are now table stakes. Vendors are racing to embed AI agents directly into CRM workflows:

• Microsoft announced its Dynamics 365 2026 release wave 1 in March 2026, adding AI capabilities across Sales, Customer Service, Contact Center, and Customer Insights.
• Adobe introduced Adobe CX Enterprise in April 2026, an agentic AI solution spanning acquisition, conversion, and loyalty.
• Freshworks launched Freddy AI Agent Studio and an MCP Gateway in May 2026, so organizations can build custom AI agents and connect them to enterprise apps.
• Insightly introduced CRM Copilot in December 2025 to analyze pipeline data and automate tasks.

2. Social media becomes a service channel. Customers expect instant responses on social platforms. CRM-integrated monitoring helps brands track mentions and sentiment and resolve issues proactively, which explains the segment's 17.2% projected CAGR.
3. Mobile CRM. Especially in the U.S., sales, retail, and field-service teams increasingly rely on mobile CRM to update records and respond to customers in real time.
4. SaaS opens the door for SMEs. Budget-constrained small businesses can adopt cloud-based CRM without heavy infrastructure spending, which supports the segment's fast projected growth.

Market Drivers & Ecosystem Trends

Driver: demand for personalized, customer-centric experiences. Organizations want a unified view of customer interactions, preferences, and purchase history. CRM platforms automate sales and marketing, personalize communications, and improve retention. Combined with AI-powered analytics, omnichannel tools, and CDPs, this is accelerating adoption across industries.

Restraint: implementation and maintenance costs. Licensing, customization, data migration, ERP and marketing-tool integration, training, and security add up. These costs can delay purchasing decisions, particularly for SMEs that need a clear ROI.

Opportunity: AI, automation, and omnichannel engagement. Predictive forecasting, intelligent lead scoring, sentiment analysis, and automated service are creating room for unified platforms that combine sales, marketing, support, analytics, and customer data management.

Regional ecosystem momentum

• Asia Pacific: E-commerce expansion, a growing SME base, and government digital initiatives are fueling demand in China and India. Both are cited as key growth contributors.
• Europe: Digitalization, regulatory requirements, and local vendor and cloud investments (such as Oracle's second cloud region in France) support growth.
• Middle East & Africa: Retail and electronics brands entering the region and rapidly growing SMEs, especially in Saudi Arabia, Turkey, and Egypt, are driving adoption.

What This Means for Stakeholders

• Vendors: AI agents, CDP integration, and SME-friendly packaging are the clearest differentiators.
• Enterprise buyers: Weigh the total cost of ownership and integration complexity, not just features.
• SMEs: Cloud CRM lowers the barrier to entry, and mobile and social features are increasingly expected.
• Investors: Asia Pacific, SMEs, and social media monitoring show the strongest projected growth rates.

Need Insights Tailored to Your Strategy? Add regions, segments, or competitor detail with 20% free customization. Customize This Report

Paws, Claws, and Profit Margins: Inside the Pet Food Market

The global pet food market was valued at USD 128.7 billion in 2025. Grand View Research projects it will reach USD 135 billion in 2026 and USD 191.2 billion by 2033, a CAGR of 5.1%. Pet adoption and rising concern for pet health and wellness are driving that growth. In the U.S. alone, 71% of households owned a pet in 2025, with dogs in 51% of homes and cats in 37%.

This post covers how the market breaks down, the trends shaping it, and how the competition is positioned.

Core Market Segmentation

The report segments the market by product, pet type, category, distribution channel, and region.

By product. Dry pet food led in 2025 with a 59.1% revenue share. It has a long shelf life, is easy to handle, costs less than wet or fresh options, and is sold almost everywhere. Snacks and treats are the fastest-growing product segment at a 5.4% CAGR. Owners use treats for training and bonding, and functional versions for dental care, joint support, and digestion are gaining traction.

By pet type. Dogs accounted for 60.8% of revenue in 2025, helped by their popularity as companions and growing interest in premium, functional diets. Cats are growing at a 4.7% CAGR through 2033 as cat ownership rises and owners look for feline-specific nutrition.

By category. Traditional pet food held 86.2% of revenue, supported by affordability, brand familiarity, and mass-retail reach. Specialist veterinary nutrition is growing at 5.2% annually. More chronic conditions are being diagnosed in pets, including obesity, renal disorders, food sensitivities, and gastrointestinal issues, and vet recommendations build owner confidence in clinical diets.

By distribution channel. Pet specialty stores led with 28.5% of revenue, because knowledgeable staff can advise on special diets such as grain-free, hypoallergenic, and senior formulas. E-commerce is the fastest-growing channel at a 6.6% CAGR, driven by home delivery, subscriptions, and bulk-order perks.

By region. North America held 41.4% of revenue in 2025 on high ownership rates, premium spending, and mature retail channels. Asia Pacific is the fastest-growing region at a 6.8% CAGR, led by China, which accounted for 34.3% of regional revenue. Central & South America (6.3% CAGR) and the Middle East & Africa (5.6% CAGR) are also expanding on urbanization and modern retail growth.

Defining Industry Trends

1. Pet humanization is pushing owners toward premium. Owners increasingly treat pets as family. They read ingredient lists, check protein sources, and look for functional ingredients such as probiotics, prebiotics, antioxidants, and vitamins.
2. Nutrition is becoming preventive health care. Concerns like obesity, joint health, and digestive wellness are moving food choices beyond basic feeding. Osteoarthritis alone is reported to affect over half of dogs and cats globally.
3. Personalization is the biggest opportunity. Demand is growing for formulations tailored to breed, size, age, and life stage, such as puppy, kitten, and senior diets, plus mobility and oral health. Supplement-style purchases are heavily influenced by the product's health-benefit claim, so targeted functionality sells.
4. Convenience and online buying are reshaping habits. Portion-controlled and single-serve formats, subscriptions, and wider online selection all make feeding easier. Retailers like Zooplus and Bitiba show how strong online pet food retail has become in Europe.
5. Price sensitivity is the main headwind. In July 2025, 42% of pet owners called high pet food prices a significant challenge, rising to 45-46% in lower-income households. Premium brands face pressure from value-oriented and private-label alternatives.
6. Clean labels and sustainability matter more. In Europe, brands are leaning into transparent, human-grade ingredients and free-from claims, mirroring clean-eating trends in human food.

Want to see the full market estimates, forecasts, and company insights? Download Free Sample

Competitive Landscape

The market is moderately consolidated. Multinationals compete alongside regional and specialized players, and most are investing in R&D, new recipes, marketing, and M&A.

Established players include The J.M. Smucker Company, Nestlé Purina, Mars, Incorporated, Hill's Pet Nutrition, and General Mills. They expand across dry, wet, snacks, and specialized nutrition. Their advantages are brand recognition, scale, and broad distribution. Their weaknesses are high operating costs, complex supply chains, exposure to ingredient and packaging price swings, and pressure from private labels.

Emerging players include LUPUS Alimentos, Total Alimentos, WellPet LLC, The Hartz Mountain Corporation, and Simmons Foods. They focus on specialized and value-oriented products, private-label manufacturing, and regional expansion. They can develop products quickly and know their regions well, but they have a smaller global footprint and fewer financial resources.

Recent moves worth noting:

• In June 2025, General Mills extended its Blue Buffalo brand into a fresh, minimally processed pet food line.
• In 2024, Nestlé Purina commissioned a 1.3-million-sq-ft manufacturing plant in North Carolina to add capacity and improve efficiency and sustainability.

The Bottom Line

Pet food is growing steadily, with the biggest openings in functional and life-stage nutrition, veterinary diets, treats, e-commerce, and Asia Pacific. Winners will balance premium innovation against affordability.

Have questions about the data or need market insights tailored to your strategy? Speak to Analyst

Beyond the Brackets: How the Clear Aligners Market Is Rewriting Orthodontics

Straight teeth used to mean metal brackets and wires. Today a growing share of patients choose a series of nearly invisible, removable trays. According to Grand View Research, the clear aligners market is on track for one of the fastest growth runs in medical devices.

Market Overview & Key Stats

The clear aligners market has moved from a niche cosmetic option to a core part of modern orthodontic care. Demand is rising on several fronts at once. Adults want discreet, convenient treatment that fits around work and social life. Dentists and orthodontists are adopting digital workflows such as intraoral scanning, AI-assisted planning and in-house production. New entrants and established dental companies keep widening the range of cases aligners can treat. Together, these forces are pushing the market into a sustained, double-digit growth phase, with North America leading in revenue today and Asia Pacific set to expand fastest as dental infrastructure and incomes grow.

Snapshot of the numbers:

• Market size, 2025: USD 5.5 billion
• Estimated size, 2026: USD 6.6 billion
• Forecast, 2033: USD 17.9 billion
• CAGR (2026–2033): 15.2%
• North America's revenue share (2025): 50.0%
• Fastest-growing region: Asia Pacific

What's driving demand?

• Adult orthodontics is booming. Adults increasingly value aesthetics, comfort and discretion, and they are moving away from fixed braces.
• There is a large untreated population. A systematic review of 47 studies found malocclusion in about 54% of preschool-aged children worldwide. That is a long pipeline of future teen and adult patients.
• Dental disease carries a large economic burden. A 2024 estimate put the global cost of dental diseases at USD 710 billion, reflecting a large pool of people needing treatment.
• Consumer behavior has shifted. Patients cite discreet appearance, removability, easier hygiene and comfort. Social media, dentist recommendations, financing options and direct-to-consumer models are speeding adoption.

Aligners are not a perfect fit for every case, though. Clinical reviews note that predictability varies with the type of tooth movement required.

Who's shaping the market

The competitive field spans orthodontic giants, dental distributors and fast-growing regional brands. Key players include:

• Align Technology
• Envista (Ormco Corporation)
• Institut Straumann AG
• 3M / Solventum
• Dentsply Sirona
• Henry Schein
• Angel Aligner
• Shanghai Smartee Denti-Technology
• SCHEU-DENTAL, Great Lakes Dental Technologies, DynaFlex and Modern Me GmbH

These companies compete on digital innovation, materials science and clinical partnerships. The sector also sees moderate-to-high merger and partnership activity, as companies combine software, intraoral scanning and materials expertise into integrated digital ecosystems.

Want to see the data first? Explore market estimates, trend analyses and forecasts in the free sample. Download Free Sample

The technologies changing treatment

1. Artificial intelligence. A 2025 scoping review of 41 clinical studies found AI is now used for automated tooth segmentation (with accuracy approaching 98%), merging CBCT and intraoral scan data, predicting outcomes and remotely monitoring progress. Other research suggests AI can reduce labor and material costs and speed up production.
2. Direct 3D printing. The industry is moving from thermoformed trays to directly printed aligners. Printing offers greater precision, customization, speed and less waste, though material safety, long-term performance and industry standards remain open challenges.
3. Recent launches show the pace of change:

• March 2025: LuxCreo introduced the 4D Aligner, described as the first MDR/CE Class IIa-certified directly 3D-printed aligner, enabling same-day production.
• September 2025: Medit launched Medit Aligners, integrated with its orthodontic suite for chairside, same-day starts.
• September 2025: Ormco introduced Spark Junior, a two-phase system for children and teens.
• July 2025: Align Technology launched an aligner with integrated occlusal blocks for mandibular advancement in growing patients.
• November 2024: Solventum launched the first 3D-printed aligner attachments.
• September 2024: OrthoFX launched NiTime in India, requiring just 9–12 hours of daily wear versus roughly 22 for conventional aligners.

The research pipeline is also broad. Ongoing trials cover skeletal open bite, Class II correction, accelerated tooth movement and direct-printed versus thermoformed aligners.

Core Market Segments & Demographics

By age

Adults led with a 65.1% share in 2025, driven by untreated malocclusion and rising aesthetic awareness. Teens are the fastest-growing segment. A 2025 meta-analysis of adolescent interceptive treatment reported arch expansion of about 3.0–3.5 mm and patient and parent satisfaction of 85–92%.

By material

Polyurethane held 67.7% of the market in 2025, valued for flexibility, transparency and consistent force delivery. PETG is expected to grow significantly, thanks to its clarity, stain resistance and cost-effectiveness for value-tier brands.

By end use

Standalone practices led in 2025, helped by dentists shifting toward private, higher-margin elective care. In the UK, strained NHS dentistry is accelerating that shift. Group practices are forecast to grow fastest, thanks to centralized planning, digital infrastructure and multi-location patient acquisition.

By distribution channel

Offline channels held 86.0% of revenue as clinics expand into tier-2 and tier-3 cities. Online is the fastest-growing channel, powered by virtual consultations, AI-based planning and home impression kits. Complex cases still keep hybrid care dominant.

By region

• North America (50.0% share): advanced dental infrastructure, early adoption of intraoral scanners and high disposable income. The U.S. is the largest country market.
• Europe: steady growth, with private practices and 3D printing on the rise.
• Asia Pacific: the fastest growth through 2033. China is both a large market and a manufacturing hub. India's market is expanding on rising awareness and digital dentistry adoption, though malocclusion studies there vary widely by region and method.
• Latin America and MEA: moderate growth, with Brazil, Mexico, the UAE and Saudi Arabia emerging, tempered by cost sensitivity and specialist shortages.

The Bottom Line

With AI-driven planning, 3D-printed aligners, a growing adult and teen patient base and fast-growing emerging markets, clear aligners are becoming a mainstream orthodontic standard. Manufacturers, clinics, investors and suppliers all have good reasons to understand where this market is headed.

Need insights tailored to your strategy? Add the regions, segments or competitor details that matter to your business, with 20% free customization. Customize This Report

The Medical Imaging Market Is Getting a Brain Transplant, and It's AI

Medical imaging sits at the center of modern diagnosis. From spotting a fracture to planning a tumor resection, clinicians depend on imaging at almost every stage of care. According to Grand View Research, the medical imaging market is entering a steady growth phase, driven by an aging population, rising chronic disease, and a wave of AI-enabled equipment.

Key Technologies and Modalities

The market spans five major technology groups:

• X-ray devices: radiography, fluoroscopy, and mammography.
• Ultrasound: handheld, compact, and cart/trolley-based systems.
• Computed tomography (CT): high-, mid-, and low-end slice systems, plus cone beam CT.
• Magnetic resonance imaging (MRI): closed and open systems.
• Nuclear imaging: SPECT and PET.

MRI led the market in 2025 with a 27.9% revenue share. It is widely used for the brain, spine, heart, breast, abdomen, and musculoskeletal structures. Advances such as diffusion tensor imaging, perfusion imaging, functional MRI, and intraoperative MRI keep widening its clinical use. Deep learning is also speeding up scans. GE HealthCare's FDA-cleared Sonic DL is one example, enabling high-quality cardiac imaging within a single heartbeat.

CT is the fastest-growing modality. It delivers high-resolution views of organs, tissue, and bone, and newer systems are faster, more accurate, and safer. Cardiac CT is gaining particular momentum, helped by guideline support for coronary CT angiography in evaluating chest pain.

By application, orthopedic imaging held the largest share (32.4%) in 2025, supported by rising bone injuries and road accident trauma. Cardiology is projected to grow fastest.

Want deeper insights? The full Grand View Research report covers 20+ countries, segment-level forecasts, and competitive profiles. Download Free Sample to explore the data and report structure.

Major Growth Drivers

1. An aging global population. Older adults face higher risks of heart disease, stroke, cancer, and osteoporosis, all of which rely on imaging. The UN expects the number of people aged 65 and above to double over the next 30 years, reaching 1.6 billion by 2050.
2. Rising chronic disease burden. In the U.S. alone, an estimated 1.96 million new cancer cases were projected for 2023. The WHO reports roughly 3.6 billion diagnostic tests performed worldwide each year. Surgeons also increasingly rely on preoperative MRI and CT to map tumor margins.
3. Demand for early, accurate diagnosis. Imaging is non-invasive and often preferred over alternatives such as biopsies and blood tests, which gives it a durable advantage.
4. Sustained R&D and investment. Public and private funding is pouring into next-generation systems, from Canon's in-house-built Vantage Galan 3T MRI to United Imaging's USD 490 million R&D and manufacturing campus in Shanghai.

A note on restraints: high equipment cost remains a barrier, particularly in low- and middle-income countries. Providers are responding by evaluating total cost of ownership rather than sticker price alone.

Market Overview & Core Numbers

• Market size, 2025: USD 43.5 billion
• Estimated market size, 2026: USD 45.5 billion
• Projected market size, 2033: USD 64.7 billion
• CAGR, 2026–2033: 5.1%
• Largest region (2025): North America, 36.3% share
• Fastest-growing region: Asia Pacific
• Leading technology: MRI, 27.9% share
• Leading application: Orthopedics, 32.4% share
• Leading end-use: Hospitals, 42.0% share

Regional picture: North America leads thanks to high healthcare spending, strong reimbursement, and heavy chronic disease incidence, and it is expected to keep that position. Asia Pacific should grow fastest, fueled by population growth, expanding R&D, and demand for both conventional and advanced systems. In India, for instance, Philips has expanded its manufacturing and R&D facility in Maharashtra.

End-use picture: Hospitals dominate because they invest heavily in advanced imaging. Diagnostic imaging centers are growing at the highest rate, driven by greater awareness of cancer and neurological conditions and rising CT and MRI volumes.

Dominant Market Trends

AI is becoming the core of the imaging workflow. AI algorithms analyze complex images faster, support early detection, and ease radiologist workload. GE HealthCare's work with Mass General Brigham on foundation models, and its SonoSAMTrack model for ultrasound segmentation, show where the industry is heading. Its acquisition of Caption Health also added AI-guided ultrasound.

Portable and point-of-care imaging is moving care beyond the hospital. Examples include Siemens Healthineers' mobile 1.5T MAGNETOM Viato.Mobile MRI, portable X-ray systems with built-in workstations, and Canon's lightweight Aplio me ultrasound.

Immersive visualization is emerging. Visage Imaging's Visage Ease VP brings diagnostic image review to Apple Vision Pro, and Philips' ClarifEye offers augmented reality surgical navigation.

Consolidation and partnerships are accelerating. Canon acquired NXC Imaging and partnered with Olympus on endoscopic ultrasound, reflecting the industry's push to combine capabilities quickly.

A concentrated, mature, regulated industry. A few major players dominate, innovation is incremental but steady, and stringent FDA and EMA standards make bringing new technologies to market slow and costly.

Key Global Players

The market is led by established names, including:

• GE HealthCare
• Koninklijke Philips N.V.
• Siemens Healthineers
• Canon Medical Systems Corporation
• Mindray Medical International
• FUJIFILM VisualSonics Inc.
• Carestream Health
• Hitachi
• Samsung Medison Co., Ltd.
• Koning Corporation
• PerkinElmer Inc.
• Konica Minolta
• Esaote
• Hologic, Inc.
• Varex Imaging

These companies compete through product launches, AI integration, expansion, and partnerships. Recent examples include Philips' AI-powered CT 3500 for high-volume screening and Canon's new Aquilion ONE / INSIGHT Edition and Aquilion Serve SP CT scanners.

The Road Ahead

With a projected rise from USD 45.5 billion in 2026 to USD 64.7 billion by 2033, medical imaging offers opportunity across modalities, applications, and regions. The winners will be those who pair clinical precision with AI, portability, and cost-conscious design.

Speak to Analyst to discuss how these findings apply to your strategy.

Inside the Permanent Magnets Market: Where Invisible Forces Meet Billion-Dollar Bets

Permanent magnets are the quiet workhorses of the modern economy. Unlike electromagnets, they hold their magnetic field without any external power, which makes them indispensable wherever efficiency, compactness and reliability matter. They sit inside EV traction motors, direct-drive offshore wind turbines, industrial robots, MRI scanners, aerospace actuators and the earbuds in your pocket. As the world shifts toward electrification, renewable energy and automation, demand for stronger and smaller magnets keeps rising.

That growth comes with a catch. Magnet supply chains are among the most geopolitically exposed in advanced manufacturing, with refining and production heavily concentrated in a single country. Governments and manufacturers are now racing to build alternative sources, from domestic mining to recycling to rare-earth-lean designs, and the outcome will shape who wins in this market.

This post, based on Grand View Research's analysis, covers where magnets are made, who makes them, and where the market is heading.

1. Regional Landscape & Supply Chain

Asia Pacific dominates. The region held a 75.6% revenue share in 2025, with China the largest country market. It is also expected to grow at the fastest CAGR through 2033. Demand comes from EV production, wind installations and consumer electronics. China sold over 13 million EVs in 2025 alone, out of 20.7 million globally.

The concentration risk is real. China controls roughly 70% of global refining capacity. Export controls on heavy rare earths such as dysprosium and holmium in 2025 pushed up price volatility and forced several Western OEMs to cut production or rethink sourcing.

Other regions are responding with "mine-to-magnet" strategies:

• North America: The U.S. is the largest regional market, and domestic mining and processing is being rebuilt, including Mountain Pass in California. Incentives for EV manufacturing support this.
• Europe: Heavily import-dependent for rare earths, Europe is backing industrial projects, recycling and source diversification, with EV production as the main magnet consumer.
• Latin America: Brazil holds the world's second-largest rare earth reserves. The CIT SENAI ITR facility in Minas Gerais, operating since 2024-2025, is the Southern Hemisphere's first plant making sintered NdFeB magnets at pilot scale (about 100 tons a year).
• India: In January 2026, India announced plans to start domestic rare earth magnet manufacturing by 2028, backed by a USD 860 million scheme targeting 6,000 metric tons a year. The aim is to cut an 80-90% dependence on China.

Material mix: NdFeB accounts for 71.2% of the market because of its unmatched power density in EV motors and direct-drive wind turbines. SmCo is the fastest-growing material, driven by aerospace and defense needs at temperatures between 350°C and 550°C.

Want the Full Picture? The full Grand View Research report covers segment forecasts by material, application and region (2021-2033), country-level analysis for 10 countries, and profiles of the key players. Download Free Sample Report: preview the market data, trend analysis and forecasts.

2. Key Industry Participants

The market combines global specialists, regional manufacturers and engineered-solution providers. Grand View Research profiles ten companies:

• Adams Magnetic Products Co.
• Earth-Panda Advance Magnetic Material Co., Ltd.
• Arnold Magnetic Technologies
• Daido Steel Co., Ltd.
• Eclipse Magnetics Ltd.
• Electron Energy Corp.
• Goudsmit Magnetics Group
• Hangzhou Permanent Magnet Group
• Magnequench International, LLC
• Ningbo Yunsheng Co., Ltd.

Two examples show the range. Eclipse Magnetics (UK) focuses on magnetic separation, lifting and holding, using NdFeB, SmCo, ferrite and alnico. Electron Energy Corp. (U.S.) serves aerospace, defense and medical customers with SmCo and neodymium magnets, along with machining, coating and custom assemblies.

The competitive edge is moving from volume to supply security. Companies with non-China sourcing, recycling capability or rare-earth-lean designs are gaining strategic value.

3. Market Size Projections

The global permanent magnets market was valued at USD 25.9 billion in 2025 and is estimated at USD 28.0 billion in 2026. It is projected to reach USD 47.4 billion by 2033, growing at a 6.8% CAGR from 2026 to 2033.

What drives the growth:

• Electrification: NdFeB is essential to EV traction motors.
• Renewables: Renewable capacity is projected to grow by almost 4,600 GW between 2025 and 2030. Offshore wind is expected to double to 140 GW, and direct-drive turbines use hundreds of kilograms of NdFeB per megawatt.
• Efficiency regulation: Permanent magnet synchronous motors are 15-30% more efficient than induction motors.
• Automation and miniaturization: Robotics, haptics, wearables and MRI all need smaller, stronger magnets.

By application: Consumer goods and electronics led with a 26.1% share in 2025. Energy is the fastest-growing segment.

Opportunities: Rare-earth-free and "thrifting" designs, and recycling. Recycled magnets could supply up to 10% of global demand by the mid-2030s.

The Bottom Line

The permanent magnets market is on a solid growth path toward USD 47.4 billion by 2033, but the winners will be the players who secure raw material access and diversify supply.

Customize This Report: add regions, segments or data points that fit your strategy.

The Brain Health Supplements Market Has a Proof Problem (and a Plan)

Cognitive wellness has moved from a niche interest to a mainstream health priority. Aging populations, rising stress and digital overload are pushing consumers to look for nutritional support for memory, focus, mood and sleep. Here is where the market stands and where it is headed, based on Grand View Research's latest analysis.

Current Valuation and Future Projections

The global brain health supplements market was valued at USD 12.4 billion in 2025. It is estimated at USD 14.0 billion in 2026 and is projected to reach USD 31.4 billion by 2033, a CAGR of 12.2% from 2026 to 2033.

Regional picture

• North America led in 2025 with a 38.4% revenue share, supported by strong health consciousness and demand for personalized, clinically backed formulations.
• Asia Pacific is the fastest-growing region, projected at a 16.1% CAGR through 2033. China, India and Japan are the key markets, driven by preference for natural products, preventive healthcare and rising dementia prevalence.
• Europe is growing on the shift from synthetic to naturally derived supplements, with France the largest country market in 2025.

Segment highlights

• Product: Herbal extracts held the largest share (42.5%) in 2025, as consumers favor botanicals such as ginkgo, turmeric and sage. Vitamins and minerals are the fastest-growing product group.
• Form: Capsules led with a 31.3% share, while softgels are the fastest-growing format at a 14.8% CAGR.
• Application: Stress and anxiety is among the fastest-growing use cases, with a projected 14.6% CAGR.
• Channel: Pharmacies and drug stores led with a 48.8% share. Online is growing fastest, at a 14.6% CAGR, helped by subscriptions and faster delivery.

Go Deeper with the Full Report. The Grand View Research report covers segment forecasts to 2033, country-level data across 20+ regions, company profiles and competitive benchmarking. Download the Free Sample to preview the report's data and structure.

Industry Challenges and Context

What is driving demand. Mental health awareness is rising. The WHO estimates that around 280 million people live with depression, and anxiety disorders affect about 359 million. In the U.S., roughly 7.4 million people live with Alzheimer's dementia, and the biological changes can begin up to 20 years before symptoms appear. That long window fuels interest in prevention and healthy brain aging. Demand is also broadening beyond older adults to students, professionals and athletes.

The main challenge: proof. Limited clinical validation is the market's biggest restraint. Some products have been found to carry inaccurate dosages or undeclared ingredients, and overconsumption can cause adverse effects. Products with thin evidence struggle to earn lasting consumer trust.

The industry is responding with regulatory pathways and clinical research. In August 2023, Aker BioMarine received FDA new dietary ingredient status for its LYSOVETA brain health ingredient. In 2026, Dr. Goodenowe Dietary Therapeutics announced plans to take its plasmalogen-based compounds through the FDA process.

The opportunity: personalization and science. Reckitt's Neuriva Memory 3D, launched in September 2025 with clinically tested ingredients, is a good example of the shift toward targeted, evidence-based products. Grand View Research's analysts expect the strongest competitive positions to belong to companies that offer multi-benefit cognitive solutions (memory, focus, mood, stress, sleep and healthy aging) and use digital health integration to keep consumers engaged over the long term.

Prominent Industry Players

The market mixes established nutrition companies with fast-moving direct-to-consumer brands. Companies profiled in the report include:

• Nestlé Health Science
• Amway Corporation
• Reckitt Benckiser Group PLC
• NOW Foods
• Natrol LLC
• Jarrow Formulas, Inc.
• Onnit Labs, Inc. (part of Unilever)
• Quincy Bioscience, LLC
• Natural Factors Nutritional Products Ltd.
• Bayer AG

Established players bring brand trust, wide distribution and research budgets, but they carry higher compliance costs and slower development cycles. Emerging brands such as Neuriva, Mind Lab Pro, Thesis and Qualia innovate faster and lead in digital marketing and personalization, but they face limited reach and the challenge of building clinical evidence.

Recent launches show where the product pipeline is going: Bayer's Berocca Mind with Spanish sage extract (UK, November 2024), Solaray's SharpMind Memory with a clinically studied sage blend (September 2024), and Monteloeder's MINDREVIVE botanical nootropic blend (October 2024).

Investment and Business Perspective

1. Follow the evidence. Clinically substantiated ingredients and regulatory approvals are becoming the main differentiators. Companies that invest in trials and ingredient validation are better placed to command premium pricing and consumer loyalty.
2. Look at Asia Pacific. With the fastest regional growth and rising awareness in India, China and Japan, the region suits partnerships, local launches and distribution deals. DKSH's 2025 partnership to bring brain health products to Hong Kong and Macau shows the model.
3. Bet on formats and channels that are growing. Softgels, gummies and other convenient formats, along with online and subscription sales, are gaining share. Pharmacies remain important for credibility, so an omnichannel approach makes sense.
4. Target the fastest-growing needs. Stress and anxiety, sleep and recovery, and healthy aging offer room for differentiated, multi-benefit products.
5. Build for retention. Personalization and digital health tools can turn one-time buyers into long-term customers, a point the analysts stress.
6. Manage the risks. Regulatory scrutiny, claims substantiation and quality control affect brand equity. Diligence on ingredient sourcing, testing and labeling compliance is essential for investors and operators.

Speak to an Analyst to discuss how these findings apply to your strategy.

From $77.1B to $123.2B: The Adhesives And Sealants Market's Sticky Climb

Adhesives and sealants rarely get attention, but they hold together much of modern manufacturing, from car bodies and EV battery packs to corrugated boxes, kitchen cabinets, skyscraper façades and surgical devices. As industries replace welds, rivets and screws with chemical bonding, the market is entering a steady, broad-based growth phase.

Market Overview & Projections

According to Grand View Research, the global adhesives and sealants market was valued at USD 77.1 billion in 2025. It is estimated at USD 81.7 billion in 2026 and projected to reach USD 123.2 billion by 2033, a CAGR of 6.0% over 2026–2033.

Asia Pacific led in 2025 with a 36.4% revenue share, and China was the largest country market. The industry is also highly fragmented, with many small and mid-sized players competing alongside global chemical majors. That structure shapes the competitive and M&A picture discussed below.

Key Drivers & Strategic Industry Shifts

1. Construction and infrastructure demand. Residential, commercial and public infrastructure spending is the most important demand engine. Builders are swapping mechanical fasteners for adhesives and sealants that offer better durability, flexibility and structural integrity, and they use them in flooring, roofing, insulation, glazing, panel installation and waterproofing. Urbanization programs in emerging economies add to this. In Asia Pacific, the report points to India's Smart Cities Mission and PMAY, and to Indonesia's national development plan. In Europe, renovation of an aging building stock is a further tailwind.
2. Vehicle lightweighting and electrification. Automakers use structural adhesives to cut weight, improve safety and dampen vibration. The report notes that EV makers such as Tesla, BYD and NIO are using adhesives in body-in-white construction and battery assemblies, and that Henkel, 3M and Sika are scaling up in China to serve this demand.
3. The sustainability pivot. Low-VOC, water-based, solvent-free and bio-based formulations are moving from nice-to-have to necessity. Regulation and corporate sustainability targets are pushing the shift. It is also an opportunity, because bio-based chemistries are reaching applications that once needed conventional formulations, and recyclable packaging and green building add further pull.
4. Specialty and high-stakes applications. Aerospace and aviation (lightweight structural bonding, plus maintenance and repair activity), high-temperature environments, and medical uses such as surgical sealants and dental adhesives are all pushing demand toward higher-performance materials.

Headwinds to watch: Petrochemical-linked raw materials (acrylics, epoxy, polyurethane, silicones, solvents) are exposed to crude oil swings and geopolitical disruption, which squeezes margins. Tightening VOC rules also raise R&D costs and lengthen time to market.

Want the data behind this analysis? Download a Free Sample Report to see market estimates, trend analyses and forecasts across technologies, products, applications and regions.

Segment Insights

Adhesives by technology

• Reactive & others led in 2025 with a 48.7% revenue share.
• Solvent-based is forecast to be the fastest-growing technology at a 5.2% CAGR, supported by packaging, medical and tape uses.

Adhesives by product

• Acrylic led with 36.9% of revenue, thanks to its ability to bond metals, plastics, glass, ceramics and wood while resisting moisture, chemicals and UV.
• EVA is expected to grow fastest at 6.5% CAGR. It sets quickly, bonds varied substrates without water or solvents, and suits fast-paced packaging, woodworking and automotive lines.

Adhesives by application

• Paper & packaging led with 29.4%, anchored in corrugated board and carton manufacturing.
• Furniture & woodworking is the fastest-growing segment at 7.4% CAGR, driven by demand for durable, eco-friendly furniture and by hot-melt EVA, PUR and water-based systems.

Sealants by product

• Silicones led with 33.2%, including lightweighting-related automotive use.
• Acrylic sealants are the fastest growing at 6.3% CAGR, favored for their low-VOC, paintable, easy-to-apply profile in interiors.

Sealants by application

• Construction dominated with 44.8%, covering concrete joints, expansion gaps, façades and prefabricated structures.
• Packaging is growing fastest at 6.4% CAGR, as sealing solutions extend shelf life and protect against moisture, oxygen and temperature swings.

Regional snapshot: Asia Pacific leads. Latin America is expected to emerge as a high-growth region on construction and infrastructure in Brazil and Argentina. Europe is renovation-led, North America is driven by construction and automotive lightweighting, and the Middle East & Africa benefits from construction spending and automotive investment incentives, with Morocco cited as an example.

Top-Tier Competitors

The report profiles 12 companies: 3M, Ashland, Avery Dennison, H.B. Fuller, Henkel, Sika, Pidilite Industries, Huntsman, Wacker Chemie, RPM International, Dow and Kuraray.

The report splits the field into two groups:

• Established players (3M, Ashland, Avery Dennison, H.B. Fuller, Henkel, Sika, Huntsman, Wacker, RPM, Dow). Their strengths are brand recognition, broad multi-industry portfolios, strong R&D and global manufacturing and distribution. Their weaknesses are high compliance costs, raw material exposure, complex supply chains and slower commercialization. Their playbook combines capacity expansion, sustainable R&D, acquisitions and industry-specific solutions.
• Emerging players (Pidilite, Kuraray). They compete through niche and specialty technologies, bio-based chemistries and customization. They move faster and adapt more flexibly, but they have a smaller global footprint, lower bargaining power with suppliers and narrower portfolios.

For context, Henkel's portfolio includes brands such as Loctite, Teroson and Technomelt, and Dow supplies adhesive and sealant materials alongside silicones and performance materials.

The Investment & M&A Lens

A fragmented market, a 6% growth outlook and rising technical requirements make adhesives and sealants a natural consolidation arena. Recent deals and investments show where capital is going:

• H.B. Fuller / ND Industries (May 2024): The acquisition added specialty adhesives and fastener locking and sealing solutions, including the Vibra-Tite brand, plus pre-applied coating centers. It targets high-growth, high-margin segments such as automotive, electronics and aerospace.
• H.B. Fuller / Beardow Adams: The deal supports the company's European expansion, in line with regional consolidation aimed at geographic reach and portfolio depth.
• Sonoco (July 2025): A USD 30 million capacity investment aimed at packaging, automotive and industrial demand.

What this signals for investors and strategics:

1. Specialty over commodity. Engineering adhesives for electronics, EVs and aerospace command higher margins than general-purpose products.
2. Regional entry via acquisition. Buying local players is often faster than building distribution, especially in Europe and high-growth Asia Pacific and Latin America.
3. Sustainability as a valuation lever. Low-VOC and bio-based portfolios reduce regulatory risk and meet customer mandates.
4. Capacity in growth niches. Packaging, furniture and construction sealants are the fastest-growing application segments.
5. Emerging specialists as targets or partners. Niche innovators with strong polymer expertise can give larger players quicker access to new chemistries.

Key diligence risks are raw material pass-through ability, regulatory exposure by region, and customer concentration in cyclical end markets such as construction and automotive.

Final Takeaway

Adhesives and sealants are a steady compounder. Demand comes from construction, mobility, packaging and healthcare, growth is tied to lightweighting and sustainability, and a fragmented supplier base keeps consolidation active. Companies that pair specialty chemistry with regional reach are best placed to capture the next US$40+ billion of growth.

Need insights tailored to your strategy? Customize This Report: add regions, segments or data points, with 20% free customization.

The Real World Evidence Solutions Market Is Quietly Becoming Pharma's Most Valuable Asset

Clinical trials remain the gold standard for proving a therapy works, but they show only part of the picture. Real-world evidence (RWE) fills the rest by showing how treatments perform across everyday patients, settings, and timeframes. Grand View Research values the global real world evidence solutions market at USD 3.0 billion in 2025, rising to USD 3.3 billion in 2026 and USD 6.0 billion by 2033, a CAGR of 9.1%. North America led in 2025 with a 44.1% share, while Asia Pacific is expected to grow fastest.

Regulators are a big reason for this momentum. In December 2025, the U.S. FDA dropped its requirement that RWE submissions include identifiable patient-level data, so de-identified registries, claims, and EHR networks can now be considered case by case. The UK's MHRA launched an RWE Scientific Dialogue pilot in January 2025. Below, we look at what is holding the market back, what it is built on, who uses it, and who is leading it.

Systemic Challenges: The Data Problem Behind the Promise

The main obstacle is not a lack of data. Health data is growing at roughly 36% a year. The problem is that much of it is hard to use.

• Data quality and completeness. Real-world datasets often have missing values, inconsistent coding, and mixed formats across providers and countries.
• Fragmentation. Differences in clinical coding systems, disconnected EHRs, and varied care delivery practices make integration slow and costly. Combining claims and EHR data often requires heavy cleaning and normalization before the evidence is regulatory-grade.
• Regulatory scrutiny. The FDA and EMA both stress "fit-for-purpose," high-quality evidence. Poorly curated data can weaken a submission or a reimbursement case.
• Regional gaps. In Latin America, fragmented data governance and the absence of formal RWE guidelines limit progress. In the Middle East and Africa, fragmented health systems, limited local data generation, and trust in data remain hurdles, even as Saudi Arabia's SFDA advances a draft RWE framework.

The emerging fix is AI. Vendors such as IQVIA, SAS, Saama, and Veradigm are embedding AI and automation to map, clean, and standardize data, turning scattered sources into analysis-ready datasets. This is also one of the market's biggest opportunities.

Key Components & Data Sources

The market splits into two components:

1. Services (58.1% share in 2025). This is the largest segment, driven by pharma, biotech, and provider demand for outsourced RWE studies, analytics, and expertise.
2. Data sets. This segment is expected to grow at a significant rate as organizations seek to understand real-world compliance, epidemiology, and costs. It breaks down into:

• Clinical settings data (EMRs and hospital records)
• Claims data
• Pharmacy data
• Patient-powered data (patient-reported outcomes, wearables, and biometric devices)

Decentralized trials, digital therapeutics, and remote monitoring are adding longitudinal patient data, making these sources richer each year. Partnerships are also expanding access. In October 2025, HealthVerity and Claritas Rx combined de-identified claims, EMR, and lab data with specialty pharmacy and hub insights. In November 2025, Datavant and AWS launched a clean-room solution that lets life-science companies analyze multiple data sources without moving raw data.

Want the numbers behind these trends? Download a free sample of the Real World Evidence Solutions Market Report for market estimates, forecasts, and trend analysis.

Applications

• Drug development and approvals led in 2025 with a 28.7% share, as sponsors use RWE to speed development and support regulatory decisions. The FDA has also issued draft guidance on using RWD in medical device decisions.
• Medical device development and approvals.
• Reimbursement/coverage and regulatory decision-making is the fastest-growing application, as RWE frameworks for the full product lifecycle are only now being issued.
• Post-market safety and adverse event monitoring is gaining importance as therapies grow more complex. Adverse drug events are estimated to contribute to 250,000 to 300,000 deaths a year in the U.S.

Therapeutic areas

Oncology leads with about 23.1% of the market, reflecting RWE's role in lowering trial costs and improving approval odds. Cardiology is expected to grow significantly, and the market also covers neurology, diabetes, psychiatry, and respiratory care.

End users

• Healthcare companies (pharma, biopharma, and device makers) held the largest share in 2025, using RWE across clinical research, commercial, HEOR, and market access.
• Healthcare payers are the fastest-growing group. RWE already appears in around 16% of clinical findings cited by payers in specialty drug decisions, with EHR data the most cited source.
• Healthcare providers and other stakeholders round out the market.

Key Industry Players

The market is slightly fragmented. Integrated data and analytics leaders like IQVIA compete with technology and health-data firms such as Oracle and Optum, while CROs and niche data specialists add further competition. Innovation, partnership activity, and regulatory influence are all high.

Companies profiled in the report include:

• IQVIA
• Merative
• PPD Inc. (now part of Thermo Fisher)
• Parexel International Corporation
• NTT DATA, Inc.
• ICON plc
• Oracle
• Syneos Health
• Cegedim Health Data
• Medpace
• Optum Inc. (UnitedHealth Group)
• SAS Institute Inc.
• Cognizant
• Aetion (acquired by Datavant in May 2025)
• Flatiron Health
• Cytel Inc.
• Trinity

Recent moves show where competition is heading:

• Thermo Fisher launched the CoreVitas Obesity Registry in January 2026.
• Aetion listed its evidence platform on AWS Marketplace in March 2025.
• IQVIA expanded its partnership with Salesforce in April 2024.
• Parexel partnered with Palantir on AI-driven trials in April 2024.
• Atropos Health launched its Evidence Agent in October 2025, working with Stanford Health Care and Microsoft to bring RWE into clinical workflows.

The Bottom Line

RWE is moving from a supplementary tool to a core part of drug development, regulatory review, and reimbursement. The winners will be those who can turn fragmented data into trusted, regulator-ready evidence, and AI-driven integration is a big part of that.

Have questions about the market? Speak to an Analyst to discuss the findings and how they apply to your strategy.